Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...
Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) turned in stellar performances in 2018. Abbott's shares jumped 27%, while DexCom stock more than doubled. It's a different story so far this ...
With multiple COVID-19 vaccines being distributed across the world, companies focused on other medical conditions are now grabbing the Street's attention. One such disorder is diabetes, which is ...
The U.S. Centers for Medicare & Medicaid Services (CMS) has opted to cover the Freestyle Libre System from Abbott Laboratories for insulin-dependent diabetes patients. The system, which was just ...
Two companies are making life a lot easier for people with diabetes. Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) market devices that allow for convenient monitoring of blood sugar levels ...
With multiple COVID-19 vaccines being distributed across the world, companies focused on other medical conditions are now grabbing the Street's attention. One such disorder is diabetes, which is ...
Two companies are making life a lot easier for people with diabetes. Abbott Laboratories (ABT 1.18%) and DexCom (DXCM +0.97%) market devices that allow for convenient monitoring of blood sugar levels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results